RECRUITING

Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

Talk to us

Conditions

Tachycardia AtrialAtrial FibrillationAtrial Flutter With Rapid Ventricular Response

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.

Official Title

Atrial Tachycardia Reduction With Intravenous Use of Magnesium (ATRIUM) Study: Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

Quick Facts

Study Start:2024-10-07
Study Completion:2026-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06376916

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age \> 18 years or older
  2. * Able to provide informed consent
  3. * Primary diagnosis AFF RVR greater than or equal to 120 bpm
  4. * Diltiazem as rate control agent
  5. * English speaking
  1. * Hemodynamically unstable patients (SBP \<90, MAP \<65)
  2. * Impaired consciousness
  3. * End stage renal disease on hemodialysis or peritoneal dialysis
  4. * Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging
  5. * Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis
  6. * Rhythms other than AF, such as sick sinus syndrome or wide-complex ventricular response
  7. * Acute myocardial infarction
  8. * Pregnancy defined as a positive urine HCG (human chorionic gonadotropin)
  9. * Contraindications to magnesium sulfate (including myasthenia gravis)
  10. * Allergy or sensitivity to any study drugs
  11. * Previously enrolled in this trial during a different patient encounter
  12. * Withdrew from study

Contacts and Locations

Study Contact

Marc McDowell, PharmD
CONTACT
(708) 684-1078
marc.mcdowell@aah.org

Principal Investigator

Travis Hase, MD
PRINCIPAL_INVESTIGATOR
Wake Forest University Health Sciences

Study Locations (Sites)

Advocate Christ Medical Center Emergency Department (ACMC ED)
Oak Lawn, Illinois, 60453
United States

Collaborators and Investigators

Sponsor: Wake Forest University Health Sciences

  • Travis Hase, MD, PRINCIPAL_INVESTIGATOR, Wake Forest University Health Sciences

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-10-07
Study Completion Date2026-12

Study Record Updates

Study Start Date2024-10-07
Study Completion Date2026-12

Terms related to this study

Additional Relevant MeSH Terms

  • Tachycardia Atrial
  • Atrial Fibrillation
  • Atrial Flutter With Rapid Ventricular Response